Lung Non-Small Cell CarcinomaNCT07186699
Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD
An observational study of Lung Non-Small Cell Carcinoma and Thoracic Cancer, run by University of Southern California at 2 sites in United States.
Trial summary
This study will attempt to identify social facilitators and barriers to detection and treatment of non-small cell lung cancer in order to learn how a history of substance abuse or alcohol use impacts care for non-small cell lung cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Non-Small Cell Carcinoma, Thoracic Cancer
- What is being tested?
- Non-Interventional Study
- How many people
- 45 participants
- Where
- 2 sitesUnited States
- Study dates
- 29 Sep 2025to 12 Sep 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with thoracic cancers, including lung and esophageal, recruited through USC/Norris Comprehensive Cancer Center
Who may be able to join
- * Adults ≥ 18 years of age
- Histopathologic or cytologic diagnosis of thoracic cancers, including lung and esophageal
- Received or receiving curative intent treatment (e.g. surgery, radiation therapy, systemic therapy)
- Ability to understand and the willingness to sign a written informed consent
- English or Spanish speaking. Due to need to conduct semi-structured interviews which can develop into free-flowing conversations we need both participant and interviewer to be fluent
Who cannot join
- Patients with cognitive disability unable to maintain 30-60 minute conversation
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
Los Angeles General Medical Center
Los Angeles, California, 90033
Sandy Tran, 323-865-3935, sandy.tran@med.usc.edu
Brooks V. Udelsman
- Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Sandy Tran, 323-865-3935, sandy.tran@med.usc.edu
Brooks V. Udelsman
About this study
Official title: Qualitative Study on Detection and Treatment of Thoracic Malignancies in Patients With a History of Alcohol or Substance Use Disorder
This study will attempt to identify social facilitators and barriers to detection and treatment of non-small cell lung cancer in order to learn how a history of substance abuse or alcohol use impacts care for non-small cell lung cancer.
Read the detailed description
PRIMARY OBJECTIVE:
- To identify social facilitators and barriers to detection and treatment of thoracic cancers by interviewing a diverse group of patients at Keck, Los Angeles General Medical Center, and Norris Cancer Center with alcohol or substance use disorder history.
OUTLINE: This is an observational study.
Patients participate in a semi-structured interview and may participate in a follow-up focus group interview in which preliminary findings are shared and feedback is elicited on study.
- Conditions
- Lung Non-Small Cell Carcinoma, Thoracic Cancer
- Being tested
- Non-Interventional Study
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-Interventional StudyOther
Also called Non-Interventional Observational Study, Noninterventional (Observational) Study
Non-interventional study
| Study group | Role | What they receive |
|---|---|---|
| Observational | Patients participate in a semi-structured interview and may participate in a follow-up focus group interview in which preliminary findings are shared and feedback is elicited on study. Receives: Other: Non-Interventional Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Thematic saturation
Will use a Danaher framework to approach analyze interview data using NVivo software (NVivo version 11.0, QSR International). Each interview will be analyzed to identify broad themes.
Measured: Up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2025
- Study start29 Sep 2025
- Primary completion12 Sep 2027 (estimated)
- Study completion12 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Non-Small Cell CarcinomaStudies of the same condition, open and under way.
- More trials run by University of Southern CaliforniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Brooks V Udelsman, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07186699
- Sponsor's protocol ID
- 2N-25-7
- Other IDs
- NCI-2025-05477, 2N-25-7, P30CA014089
- Status last verified
- Sep 2026
- First submitted
- 10 Sep 2025
- Last updated
- 22 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Qualitative Study on Detection and Treatment of Thoracic Malignancies in Patients With a History of Alcohol or Substance Use Disorder
- ClinicalTrials.gov ID
- NCT07186699
- Acronym / sponsor ID
- 2N-25-7
- Conditions
- Lung Non-Small Cell Carcinoma, Thoracic Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 29 Sep 2025 (actual)
- Primary completion
- 12 Sep 2027 (estimated)
- Study completion
- 12 Sep 2028 (estimated)
- First posted
- 22 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will attempt to identify social facilitators and barriers to detection and treatment of non-small cell lung cancer in order to learn how a history of substance abuse or alcohol use impacts care for non-small cell lung cancer.
Detailed description
PRIMARY OBJECTIVE:
- To identify social facilitators and barriers to detection and treatment of thoracic cancers by interviewing a diverse group of patients at Keck, Los Angeles General Medical Center, and Norris Cancer Center with alcohol or substance use disorder history.
OUTLINE: This is an observational study.
Patients participate in a semi-structured interview and may participate in a follow-up focus group interview in which preliminary findings are shared and feedback is elicited on study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational | – | Other: Non-Interventional StudyPatients participate in a semi-structured interview and may participate in a follow-up focus group interview in which preliminary findings are shared and feedback is elicited on study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with thoracic cancers, including lung and esophageal, recruited through USC/Norris Comprehensive Cancer Center
Key inclusion criteria (5 listed)
- * Adults ≥ 18 years of age
Key exclusion criteria (1 listed)
- Patients with cognitive disability unable to maintain 30-60 minute conversation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-Interventional StudyAlso: Non-Interventional Observational Study, Noninterventional (Observational) StudyNon-interventional study | Other | Observational |
Primary outcome
Thematic saturation
Time frame: Up to 3 years
Will use a Danaher framework to approach analyze interview data using NVivo software (NVivo version 11.0, QSR International). Each interview will be analyzed to identify broad themes.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
Related trials for Lung Non-Small Cell Carcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
Brooks V Udelsman principal investigator
University of Southern California
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Non-Small Cell Carcinoma and Thoracic Cancer, run by University of Southern California at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Thematic saturation (time frame: Up to 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.